Whitehawk Therapeutics financials
$3.73−0.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.1M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $6.4M |
| Gross margin | — | — | — | — | — | 89.4% |
| Operating income | -$18.1M | -$23.5M | -$24.9M | -$19.5M | -$54.7M | -$15.2M |
| Net income | -$16.6M | -$22.2M | -$23.4M | -$17.6M | -$52.6M | $73.0M |
| Net margin | — | — | — | — | — | 1021.9% |
| Diluted EPS | $-0.20 | $-0.32 | $-0.34 | $-0.26 | $-0.76 | $1.83 |
| EBITDA | -$18.1M | -$23.5M | -$24.9M | -$19.5M | -$54.7M | -$15.2M |
| Operating cash flow | -$14.5M | -$22.2M | -$17.2M | -$15.4M | -$53.0M | -$11.9M |
| Free cash flow | -$14.5M | -$22.2M | -$17.2M | -$15.4M | -$53.0M | -$12.4M |
| Diluted shares | 82.9M | 69.2M | 69.3M | 69.2M | 69.1M | 39.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $85.2M | $34.8M | $37.6M | $37.9M | $144.9M | $227.6M |
| Short-term investments | $104.7M | $88.3M | $108.1M | $124.7M | $32.3M | $3.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $194.0M | $127.2M | $150.8M | $167.0M | $180.8M | $234.0M |
| Total liabilities | $11.1M | $11.1M | $14.5M | $9.8M | $8.8M | $12.3M |
| Shareholders' equity | $182.9M | $116.2M | $136.3M | $157.2M | $172.1M | $221.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology